Fluor Stock: Buy, Sell, or Hold?

81% of Fluor's $25.5B backlog was reimbursable at the end of 2025 (and 87% of the $12B added in Q4), signaling a meaningful shift away from fixed-price project risk. The company has monetized NuScale Power stock, raising $1.35B in the most recent sale and $605M previously, with ~40M shares still to sell; proceeds are being used for share repurchases to bolster earnings and balance sheet flexibility. Positive operational repositioning is offset by cyclicality risk (construction projects vulnerable in a recession) and the stock has already doubled over five years, so downside remains in adverse macro scenarios.

Analysis

The change in contract mix is a structural risk-transfer that should compress headline margin volatility but expand balance-sheet and working-capital sensitivity. Reimbursable work reduces large fixed-price downside but creates higher receivables and pass-through timing risk; monitor DSO, retainage, and any recourse financing on a quarterly cadence as the real earnings lever will shift from margin expansion to cash-conversion improvements.

Second-order winners include owners who can de-risk scope and large-tier suppliers that can push through inflation quickly; losers are contractors and bidders that remain locked into legacy fixed-price portfolios and smaller subs exposed to payment timing. Competitors that are slow to shift their bidding model will either (a) price conservatively and lose new awards or (b) take outsized project-level losses, creating acquisition targets for firms with clean balance sheets.

Two near-term catalysts will dominate price action: the pace of remaining monetization of private stakes and the cadence of buybacks/M&A deployment. The capital recycling is optionality — if management pivots to opportunistic M&A in a downturn the equity re-rating could be quick, but if they instead fund steady buybacks the EPS cushion will be slower and more binary around cyclical revenue flows.

Contrarian angle: market consensus treats the repositioning as a full de-risking; it hasn’t fully priced the new working-capital profile or the remaining monetization overhang. That leaves a trade that’s not simply long the recovery in project activity but long execution of cash-conversion mechanics (receivables, retainage release, and disciplined capital allocation) over the next 12–24 months.

Key Decisions for Investors

• Core long FLR equity (size 1–2% portfolio) with 12–18 month horizon; hedge tail risk by buying 12‑month puts ~25% OTM sized to cover 30% of the position. R/R: asymmetric — limited hedged downside (~-30%) vs potential +40–80% re-rating if cash conversion and buyback optionality materialize.
• Tactical call-spread on FLR (buy 9–12 month 30–40% OTM call, sell 9–12 month 10–20% nearer OTM call) to express optional upside from an M&A or buyback surprise; max loss = premium, target 2.5–4x payout if catalyst hits within term.
• Short SMR (size small; 0.25–0.5% portfolio) or buy short-dated puts for 3–6 months to capture residual monetization/overhang risk from remaining stake sales. R/R: high upside if selling pressure persists; risk if nuclear sector sentiment or bid support lifts the stock.
• Relative-value: long FLR / short KBR (or a fixed-price-heavy EPC peer) for 6–12 months to isolate balance-sheet and contract-mix rerating. Size pairing 1:1 notional; expect convergence if market rewards lower earnings volatility and disciplined capital allocation — downside if sector-wide revenue collapse occurs.